We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland

Delisted

NBRV was delisted on the 31st of July, 2023.

46 hedge funds and large institutions have $127M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 4546 (+1)

1% more call options, than puts

Call options by funds: $115K | Put options by funds: $114K

6% less capital invested

Capital invested by funds: $135M → $127M (-$7.45M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

47% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 17

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
1.05%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
7
Increased
9
Reduced
17
Closed
6
Calls
$115K
Puts
$114K
Net Calls
+$1K
Net Calls Change
-$48K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$25.9M +$20.1M +13,606 +196%
VC
2
Vivo Capital
California
$20.5M
O
3
OrbiMed
New York
$19.7M
NHAS
4
Novo Holdings A/S
Denmark
$14.7M
VP
5
venBio Partners
California
$10.7M
BBA
6
Baker Bros. Advisors
New York
$4.72M
Millennium Management
7
Millennium Management
New York
$4.14M -$263K -178 -5%
HIM
8
Hillhouse Investment Management
Cayman Islands
$4.04M
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$3.99M +$555K +375 +13%
RSCM
10
Rock Springs Capital Management
Maryland
$3.14M
ACP
11
Acuta Capital Partners
California
$2.81M -$120K -81 -3%
BlackRock
12
BlackRock
New York
$2.28M +$1.63M +1,099 +154%
MWNA
13
Marshall Wace North America
New York
$1.9M -$1.26M -855 -36%
USAA
14
United Services Automobile Association
Texas
$1.78M +$1.44M +972 +217%
PM
15
Prosight Management
Texas
$1.22M -$1.47M -995 -51%
GTC
16
Ghost Tree Capital
New York
$1.01M
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$847K +$825K +558 +485%
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$563K +$419K +283 +173%
Goldman Sachs
19
Goldman Sachs
New York
$381K -$182K -123 -29%
DZ Bank
20
DZ Bank
Germany
$355K +$417K +282 New
LCM
21
Laurion Capital Management
New York
$285K -$742K -502 -69%
MP
22
MSD Partners
New York
$252K
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$251K
TI
24
Trexquant Investment
Connecticut
$244K +$287K +194 New
Morgan Stanley
25
Morgan Stanley
New York
$218K +$176K +119 +216%

NBRV Hedge Fund Activity: Q1 2018 in Review

46 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2018, worth a combined $127M — down 5.5% from $135M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NBRV positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 17 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $20.1M. The largest seller was Franklin Resources, cutting an estimated $1.87M.

  • 46 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2018, up from 45 in Q4 2017.
  • Funds reported $127M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2018, down 5.5% quarter-over-quarter.
  • 7 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2018 and 6 closed out, a net change of +1 holder.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2018 was Wellington Management Group, an estimated $20.1M added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2018 was Franklin Resources, an estimated $1.87M sold.

Based on aggregated 13F filings for Q1 2018.